SG189058A1 - Clostridium difficile antigens - Google Patents

Clostridium difficile antigens Download PDF

Info

Publication number
SG189058A1
SG189058A1 SG2013021506A SG2013021506A SG189058A1 SG 189058 A1 SG189058 A1 SG 189058A1 SG 2013021506 A SG2013021506 A SG 2013021506A SG 2013021506 A SG2013021506 A SG 2013021506A SG 189058 A1 SG189058 A1 SG 189058A1
Authority
SG
Singapore
Prior art keywords
amino acid
toxin
sequence
acid sequence
difficile
Prior art date
Application number
SG2013021506A
Other languages
English (en)
Inventor
Clifford Shone
April Roberts
Helen Ahern
Michael Maynard-Smith
John Landon
Original Assignee
Health Prot Agency
Micropharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Health Prot Agency, Micropharm Ltd filed Critical Health Prot Agency
Publication of SG189058A1 publication Critical patent/SG189058A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG2013021506A 2010-10-05 2011-10-05 Clostridium difficile antigens SG189058A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1016742.7A GB201016742D0 (en) 2010-10-05 2010-10-05 Clostridium difficile antigens
PCT/GB2011/051910 WO2012046061A2 (en) 2010-10-05 2011-10-05 Clostridium difficile antigens

Publications (1)

Publication Number Publication Date
SG189058A1 true SG189058A1 (en) 2013-05-31

Family

ID=43243528

Family Applications (1)

Application Number Title Priority Date Filing Date
SG2013021506A SG189058A1 (en) 2010-10-05 2011-10-05 Clostridium difficile antigens

Country Status (10)

Country Link
US (4) US10369206B2 (enExample)
EP (1) EP2625193B1 (enExample)
JP (1) JP6377907B2 (enExample)
CN (1) CN103237807B (enExample)
AU (1) AU2011311321B2 (enExample)
BR (1) BR112013008407A2 (enExample)
CA (1) CA2812731C (enExample)
GB (1) GB201016742D0 (enExample)
SG (1) SG189058A1 (enExample)
WO (1) WO2012046061A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201016742D0 (en) 2010-10-05 2010-11-17 Health Prot Agency Clostridium difficile antigens
HUE047085T2 (hu) 2011-04-22 2020-04-28 Wyeth Llc Clostridium difficile mutáns toxinjához kapcsolódó készítmények és eljárásai
DK2714910T3 (en) * 2011-05-27 2018-02-05 Glaxosmithkline Biologicals Sa Immunogenic composition
CA2858519A1 (en) 2011-12-08 2013-06-13 Novartis Ag Clostridium difficile toxin-based vaccine
GB201206070D0 (en) 2012-04-04 2012-05-16 Health Prot Agency Clostridium difficile antigens
BR122016023101B1 (pt) * 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
US10117933B2 (en) * 2012-11-28 2018-11-06 Emergent Biosolutions Canada Inc. Antibodies against Clostridium difficile
CN103865938B (zh) * 2012-12-16 2016-10-05 山东国际生物科技园发展有限公司 艰难梭菌外毒素a羧基端序列密码子优化基因片段、表达载体构建方法及其表达蛋白的应用
US9493518B2 (en) * 2013-03-14 2016-11-15 National Health Research Institutes Compositions and methods for treating clostridium difficile-associated diseases
CN105451762A (zh) * 2013-04-22 2016-03-30 俄克拉荷马州大学评议会 艰难梭菌疫苗及使用方法
GB201309421D0 (en) * 2013-05-24 2013-07-10 Imp Innovations Ltd Polypeptides
CN103772509B (zh) * 2014-01-20 2017-01-11 山东国际生物科技园发展有限公司 一种艰难梭菌毒素a/b的融合蛋白及其编码基因与应用
WO2017040885A1 (en) * 2015-09-03 2017-03-09 The Board Of Regents Of The University Of Oklahoma Peptide inhibitors of clostridium difficile tcdb toxin
CN112512556A (zh) * 2018-01-16 2021-03-16 儿童医学中心公司 用于抑制wnt信号传导的组合物和方法
CN113195521B (zh) * 2018-12-19 2023-05-12 清华大学 Mtu ΔI-CM内含肽变体和其应用
JP7669504B2 (ja) * 2021-02-09 2025-04-28 ジョビー エアロ，インコーポレイテッド 航空機推進ユニット
CN113717263B (zh) * 2021-08-04 2022-06-07 河北医科大学第二医院 一种艰难梭菌特异性抗原肽
CN115093470B (zh) * 2022-06-30 2023-03-24 广州市乾相生物科技有限公司 内含肽Mtu RecA突变体及其在生产谷胱甘肽GSH中的应用
CN120484111B (zh) * 2025-05-14 2025-10-28 广州海绿生物技术有限公司 一种包含益生菌的组合物及其在治疗肠胃疾病中的用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
CZ296806B6 (cs) * 1994-10-24 2006-06-14 Allergan, Inc. Rozpustný fúzní protein a zpusob výroby rozpustného rekombinantního botulinového toxinu
US5919463A (en) 1995-07-07 1999-07-06 Oravax, Inc. Clostridium difficle toxins as mucosal adjuvants
WO1998059053A1 (en) 1997-06-20 1998-12-30 Queen Mary & Westfield College Immonogenic fragments of toxin a of clostridium difficile
JP2002542169A (ja) 1999-04-09 2002-12-10 テクラブ， インコーポレイテッド Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅに対する、組換え毒素Ａ／毒素Ｂワクチン
EP1358331A2 (en) 2001-02-09 2003-11-05 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Clostridium difficile vaccine
JP4588763B2 (ja) * 2004-02-06 2010-12-01 ユニバーシティー オブ マサチューセッツ クロストリジウム・ディフィシル（Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅ）毒素に対する抗体およびその使用
CN101500581B (zh) 2006-06-08 2013-10-30 科内尔研究基金会 编码艰难梭菌毒素a和毒素b受体结合域的密码子优化dna分子及其使用方法
US20120020996A1 (en) * 2008-08-06 2012-01-26 Jonathan Lewis Telfer Vaccines against clostridium difficile and methods of use
GB0921288D0 (en) 2009-12-04 2010-01-20 Health Prot Agency Therapies for preventing or suppressing clostridium difficile infection
GB201016742D0 (en) 2010-10-05 2010-11-17 Health Prot Agency Clostridium difficile antigens
HUE047085T2 (hu) * 2011-04-22 2020-04-28 Wyeth Llc Clostridium difficile mutáns toxinjához kapcsolódó készítmények és eljárásai

Also Published As

Publication number Publication date
JP2014502253A (ja) 2014-01-30
CN103237807B (zh) 2016-10-26
AU2011311321B2 (en) 2016-05-19
US20190328859A1 (en) 2019-10-31
EP2625193B1 (en) 2018-04-04
BR112013008407A2 (pt) 2016-06-21
US20130266583A1 (en) 2013-10-10
AU2011311321A1 (en) 2013-04-11
US10369206B2 (en) 2019-08-06
US20230165949A1 (en) 2023-06-01
CA2812731C (en) 2021-07-06
CA2812731A1 (en) 2012-04-12
EP2625193A2 (en) 2013-08-14
US12491239B2 (en) 2025-12-09
CN103237807A (zh) 2013-08-07
WO2012046061A2 (en) 2012-04-12
JP6377907B2 (ja) 2018-08-22
WO2012046061A3 (en) 2012-12-20
GB201016742D0 (en) 2010-11-17
US20210369830A1 (en) 2021-12-02

Similar Documents

Publication Publication Date Title
US12491239B2 (en) Clostridium difficile antigens
EP2844283B1 (en) Clostridium difficile antigens
EP2405940B1 (en) Antibodies to clostridium difficile toxins
EP2167119B1 (en) Chemically modified peptides with improved immunogenicity
MX2008015814A (es) Uso de alfa-toxina para tratar y prevenir infecciones por staphylococcus.
EP3312192A1 (en) Immunogenic compositions containing bacterial outer membrane vesicles
CN101948546B (zh) 融合蛋白SAmB及其编码基因与应用
HK1185621B (en) Clostridium difficile antigens
HK1185621A (en) Clostridium difficile antigens
HK1202805B (en) Clostridium difficile antigens